sodium thiosulfate

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Complication of Hemodialysis

Conditions

Complication of Hemodialysis, Cardiovascular Diseases

Trial Timeline

Dec 1, 2007 → Nov 1, 2009

NCT ID

NCT00568399

About sodium thiosulfate

sodium thiosulfate is a pre-clinical stage product being developed by Sanofi for Complication of Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT00568399. Target conditions include Complication of Hemodialysis, Cardiovascular Diseases.

What happened to similar drugs?

13 of 17 similar drugs in Complication of Hemodialysis were approved

Approved (13) Terminated (2) Active (3)

✅Fospropofol + Propofol/LidocaineEisaiApproved

✅Metformin + PlaceboEli LillyApproved

✅LOKELMA 5 GM Powder for Oral Suspension + PlacebosAstraZenecaApproved

✅Sugammadex + Neostigmine/GlycopyrrolateMerckApproved

✅Quadravalent human papillomavirus vaccineMerckApproved

✅Sugammadex + NeostigmineMerckApproved

✅Sugammadex 100 MG/ML [Bridion]MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00568399	Pre-clinical	Completed	Dec 1, 2007	Nov 1, 2009	Complication of Hemodialysis

Competing Products

20 competing products in Complication of Hemodialysis

See all competitors

Product	Company	Stage	Hype Score
Fospropofol + Propofol/Lidocaine	Eisai	Approved	43
exenatide	Eli Lilly	Phase 2	27
Metformin + Placebo	Eli Lilly	Approved	43
LOKELMA 5 GM Powder for Oral Suspension + Placebos	AstraZeneca	Approved	39
deep neuromuscular block	Merck	Pre-clinical	26
Sugammadex + Neostigmine/Glycopyrrolate	Merck	Approved	35
Quadravalent human papillomavirus vaccine	Merck	Approved	43
Sugammadex + Neostigmine	Merck	Approved	43
Sugammadex 100 MG/ML [Bridion]	Merck	Approved	43
Letermovir 480 mg once daily	Merck	Phase 3	44
Rocuronium	Merck	Pre-clinical	26
Everolimus + Tacrolimus + Mycophenolic acid	Novartis	Approved	39
Ranibizumab + 0.9% Sodium Chloride	Novartis	Phase 2/3	38
Aztreonam Lysine for Inhalation (AZLI)	Gilead Sciences	Approved	43
Liraglutide + Placebo	Novo Nordisk	Approved	43
Semaglutide Treatment + Sitagliptin 100mg	Novo Nordisk	Approved	39
Control group (standard hospital treatment) + Group Hydroxychloroquine + Group Hydroxychloroquine and apixaban + Group Apixaban	Pfizer	Phase 3	40
Donepezil	Pfizer	Approved	43
Finerenone Oral Tablet + Placebo	Bayer	Phase 2	39
LA-EP2006 + Neulasta®	Sandoz Group	Phase 3	37